Dosage Drug Development Pharmaceutical Manufacturing 
Express Pharma
JANUARY 17, 2025
As environmental concerns continue to intensify, the pressure on the pharmaceutical industry to reduce its overall environmental impact, particularly in final dosage forms, is growing proportionately. Lonzas comprehensive sustainability approach spans the entire value chain, from raw material selection to end-of-life solutions.
Pharmacy Times
JUNE 23, 2025
CMS is issuing unique J-codes for 505(b)(2) drugs, classifying them as sole-source products if not therapeutically equivalent. This pathway reduces submission denial risk, accelerates drug development, and offers potential market exclusivity for up to 7 years. The 505(j) pathway is how you get a multisource generic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaTech
AUGUST 1, 2025
The industry's dependence on geopolitical stability and predictable trade relationships is increasingly critical for global pharmaceutical manufacturing. Tariffs disrupt supply chains, impacting both finished products and raw materials, complicating compliance and cost forecasting. Share your voice!
PharmaTech
JULY 23, 2025
In this first segment of a multi-part interview, Jason Waite, international trade expert at Alston & Bird, outlines how recent United States tariff activity could significantly impact pharmaceutical manufacturers.
European Pharmaceutical Review
JULY 9, 2025
What is the role of a CDMO during the fill and finish stage in pharmaceutical manufacturing? We offer end-to-end services for small molecule finished dosage forms (FDFs), including sterile and non-sterile liquids, solids, and semi-solids products. Why is it important? The importance of fill and finish cannot be overstated.
PharmaTech
JULY 17, 2025
3d render, number six glowing in the dark, pink blue neon light | Image Credit: © NeoLeo - stock.adobe.com Pharmaceutical compounding, particularly in 503A and 503B environments, involves complex formulation and regulatory challenges far beyond academic theory. antineoplastics, allergens).
European Pharmaceutical Review
APRIL 9, 2024
Delpharm has acquired the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas. The 31,600 square meter facility produces some 40 million finished solid dosage forms each year, including tablets, capsules and pellets. The company employs more than 6,500 people, generating revenues of €1.1
Expert insights. Personalized for you.
Let's personalize your content